A5020861301- Gut microbiota and health
- Dialysis and Renal Disease Management
- Pharmacological Effects and Toxicity Studies
- Veterinary Medicine and Surgery
- Nutrition and Health in Aging
- Folate and B Vitamins Research
- Heart Failure Treatment and Management
- Diabetes and associated disorders
- Human-Animal Interaction Studies
- Clostridium difficile and Clostridium perfringens research
- GDF15 and Related Biomarkers
Uppsala University
2020-2021
Science for Life Laboratory
2020
Gut dysbiosis in patients with chronic kidney disease (CKD) may induce inflammation and increase morbidity. Phosphate-binding agents, generally used CKD, potentially change the composition of gut microbiota. This study aimed to compare microbiota hemodialysis treated ferric citrate or calcium carbonate. The stool was investigated (n = 8) carbonate 46) using 16S rRNA gene amplicon sequencing profiling linear discriminant analysis effect size. Further predictive functional microbial...
Preventing sudden cardiac death (SCD) due to acute myocardial infarction (MI) in previously healthy patients is challenging. Proteomic analysis may lead an understanding of biological mechanisms and provide predictive biomarkers.In this prospective, nested case-control study from northern Sweden, 87 candidate cardiovascular protein biomarkers were studied 244 individuals who later died within 24 h incident MI referents without individually matched for age, sex date health examination alive...
Abstract Objective To investigate whether dog and cat owners their pets share a risk of developing diabetes. Design Cohort study. Setting Register based longitudinal study, Sweden. Participants 208 980 owner-dog pairs 123 566 owner-cat identified during baseline assessment period (1 January 2004 to 31 December 2006). Main outcome measures Type 2 diabetes events in pets, including date diagnosis the follow-up 2007 2012). Owners with type were by combining information from National Patient...
β-blockers are commonly prescribed to treat cardiovascular disease in hemodialysis patients. Beyond the pharmacological effects, have potential impacts on gut microbiota, but no study has investigated effect Hence, we aim investigate microbiota composition difference between β-blocker users and nonusers Fecal samples collected from patients (83 110 nonusers) were determined by 16S ribosomal RNA amplification sequencing. Propensity score (PS) matching was performed control confounders. The...
Abstract Background: β-blockers are commonly prescribed medications to treat cardiovascular disease and prevent sudden cardiac death during hemodialysis. Beyond the medication effects on host, no study has investigated impact of β-blocker gut microbiota in hemodialysis patients. Results: The users had a higher proportion diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, heart failure, cerebrovascular concurrent than non-users. After propensity score (PS) matching, there...